Aug 17 (Reuters) - U.S. drug developer Novavax Inc said on Monday that it is starting a mid-stage study of its experimental COVID-19 vaccine in South Africa, as the country experiences a surge in coronavirus cases.
The Phase 2b trial study of NVX-CoV2373 will be conducted on about 2,665 healthy adults and will evaluate the safety and immunogenicity in about 240 medically stable, HIV-positive adults, the company said in a statement.
South Africa is fifth worst affected country with 583,653 coronavirus cases and 11,677 deaths, according to a Reuters tally. Novavax said it intends to initiate the Phase 2 portion of this trial in the United States and Australia in the near future and that it would include about 1,500 candidates.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
COVID-19 LIVE UPDATES | Alarm over state instruction to test bodies for Covid-19All the Covid-19 news from SA and around the world
Read more »
South Africa goes to Covid-19 level 2 on MondayPresident Ramaphosa drops most of the restrictions that have been in place for the last five months, citing ‘signs of hope’.
Read more »
South Korea accuses religious sect leader as Covid-19 cases surgeSouth Korea accused the leader of a religious sect on Sunday of violating self-isolation rules and obstructing investigations into the country's biggest outbreak of new coronavirus in five months.
Read more »
South Korea accuses religious sect leader as Covid-19 cases surgeSouth Korea accused the leader of a religious sect on Sunday of violating self-isolation rules and obstructing investigations into the country's biggest outbreak of new coronavirus in five months.
Read more »
Jacinda Ardern orders delay in New Zealand poll as new Covid-19 cases reportedWith nearly a third of New Zealand’s five-million people under lockdown in Auckland, parties have complained that they cannot campaign
Read more »